05/26/2022 | Press release | Distributed by Public on 05/25/2022 16:18
Today's Information |
Provided by: TaiMed Biologics Inc. | |||||
SEQ_NO | 1 | Date of announcement | 2022/05/26 | Time of announcement | 06:12:52 |
Subject |
TaiMed received the official approval letter from US FDA for the pre-approval inspection (PAI) of TaiMed cGMP monoclonal antibody facility |
||||
Date of events | 2022/05/25 | To which item it meets | paragraph 53 | ||
Statement |
1.Date of occurrence of the event:2022/05/25 2.Company name:TaiMed Biologics Inc. 3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head Office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence: TaiMed today received the official approval letter from the US FDA of the pre-approval inspection (PAI) of the company's new cGMP monoclonal antibody manufacturing and testing facilities in Taiwan. The PAI was conducted on April 18 - 22, 2022 by the Agency and resulted in no Form 483 observations. This excellent outcome demonstrates TaiMed's competence and readiness in full-scale clinical and commercial contract manufacturing. With its 4 x 2,000L single-use bioreactors, full downstream purification and state-of-the-art QC testing facilities, the company announced previously that it is entering the CDMO business in addition to supporting its own monoclonal antibody development programs. TaiMed will participate in the BIO International in San Diego in June and the Taiwan Biotechnology Exhibition in Taipei in July to promote its CDMO services and meet with clients. 6.Countermeasures:None 7.Any other matters that need to be specified: New drug development requires a long process and sizeable investments with no guarantee of success, which therefore may pose substantial investment risks. Investors are advised to exercise caution and conduct thorough evaluation. |